Self-monitoring practice in patients with type 2 diabetes mellitus: data from regional mobile diabetes centre

Aims. To determine popularity and variants of blood glucose self-monitoring in patients with type 2 diabetes mellitus (T2DM) as wellas its correlation with efficiency of antihyperglycemic therapy. Materials and methods. Current study was carried out within the framework of mobile diabetes centre p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alexander Vladimirovich Petrov, Alena Alexandrovna Kalinnikova, Lyudmila Alexandrovna Suvorova, Leonid Grigor'evich Strongin, Daria Vladimirovna Logutova, Sergey Petrovich Glebov
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2012
Materias:
Acceso en línea:https://doaj.org/article/9b1fccaefac4499dac2e5dede0d71643
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Aims. To determine popularity and variants of blood glucose self-monitoring in patients with type 2 diabetes mellitus (T2DM) as wellas its correlation with efficiency of antihyperglycemic therapy. Materials and methods. Current study was carried out within the framework of mobile diabetes centre project. We analyzed 545 patients,assessing their clinical status, laboratory test results (including HbA1c levels) and self-monitoring frequency. Results. 49% of patients reported regular self-monitoring, while 25% conducted monitoring of both fasting and postprandial bloodglucose levels. Percentage of patients performing self-monitoring was found to be independent of age and length of diabetes experience,but correlated with insulin therapy and rating of chronic diabetic complications. Self-monitoring was associated with lower rate ofdiabetic decompensation and was much more common among patients on insulin therapy, being associated with statistically significantreduction of HbA1c levels. Conclusion. Self-monitoring is associated with greater efficiency of antihyperglycemic treatment in patients with T2DM on insulintherapy, as well as in those receiving oral agents only.